The Global Health Body Issues Alert Over Acute Lack of Obesity Jabs

Less than one in 10 individuals who could benefit from GLP-1 drugs including Wegovy can access them, caution the global health agency as it publishes its first guidance on the drugs.

With in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for broader and more equitable access to GLP-1 medication.

Per forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.

"Our new guidelines acknowledges that obesity is a lifelong illness that can be treated with comprehensive and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and supply-chain constraints are key barriers to broad access to the injections that can assist patients in reducing considerable weight, says the organization.

Weight-Loss Drug Supply Crisis

Even under the present most optimistic scenario, the manufacturing of these medications could only cover approximately 100 million people – under 10% of the global need, per the health organization.

The recommendation urges countries and companies to widen availability, by strategies including voluntary licensing.

A patent on the active ingredient – the core component of Novo Nordisk's Wegovy – is set to lapse in a number of countries in 2026.

The Way Obesity Drugs Function

These medications mimick a body's own hormone to slow digestion, suppress the appetite and increase the sense of being full so users consume fewer calories.

Individuals commonly begin shedding pounds within a few weeks of commencing the regular doses.

Research indicates people may put most of the weight back on after a year of stopping the drug, because their typical appetite return.

Being overweight or obese increases your risk for developing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.

Excess weight concerns individuals in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the WHO.